UMN-0501 is a cell culture based H5N1 avian influenza vaccine, currently under preparation for Phase III clinical trial in Japan.
UMN-0502 is a cell culture based seasonal influenza vaccine, under preparation for Phase I/II clinical trial in Japan.
Under the agreement, Astellas will lead the further development and bear all the costs.
UMN Pharma will be responsible for manufacturing, supply of the final commercial products to Astellas, and Astellas will be selling the commercial products.